Why the study?
Polo-like kinase 4 inhibitors are emerging as promising antineoplastic agents, but their effectiveness against Ewing's sarcoma remains to be established.
PLK4 inhibitors CFI-400945 and centrinone demonstrate preclinical efficacy against Ewing's sarcoma cells regardless of p53 status, providing a rationale for in vivo evaluation.
Answers are grounded in this paper and cite their sources.
Supports PLK4 inhibition for Ewing's sarcoma preclinical development; leaves open in vivo efficacy and clinical translation irrespective of TP53.
PURPOSE: Polo-like kinase 4 (PLK4) inhibitors, such as CFI-400945 and centrinone, are emerging as promising antineoplastic agents. However, their effectiveness against Ewing's sarcoma, a highly aggressive childhood cancer, remains to be established. METHODS: CFI-400945 and centrinone were tested in three Ewing's sarcoma cell lines with different TP53 status. Effects were assessed by flow-cytometric analyses of cell death, dissipation of the mitochondrial transmembrane potential and cell cycle distribution, by cell viability assay as well as by caspase 3/7 activity measurement, by immunoblotting and by immunofluorescence microscopy. RESULTS: CFI-400945 and centrinone elicited cell death in p53 wild-type and mutant Ewing's sarcoma cells. Both agents induced mitochondrial membrane depolarisation, caspase 3/7 activation, PARP1 cleavage and DNA fragmentation, indicating an apoptotic form of cell death. In addition, the PLK4 inhibitors induced a G2/M cell cycle arrest, particularly when cell killing was attenuated by the pan-caspase inhibitor z-VAD-fmk. Moreover, CFI-400945 treatment produced polyploidy. CONCLUSION: Our findings show that PLK4 inhibitors were effective against Ewing's sarcoma cells in vitro and thus provide a rationale for their evaluation in vivo.
No takes yet. Share an insight, caveat, or question.
Kerschner-Morales et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: